Phase 1 study of combination pexidartinib and sirolimus to target tumor associated macrophages in unresectable sarcoma and malignant peripheral nerve sheath tumors

CONCLUSIONS: Pexidartinib can be safely administered with sirolimus. These findings support further investigation of this combination to determine clinical efficacy. Clinicaltrials.gov identifier NCT02584647.PMID:34321280 | DOI:10.1158/1078-0432.CCR-21-1779

Source: Clinical Cancer Research - July 29, 2021 Category: Cancer & Oncology Authors: Gulam A Manji Brian A Van Tine Shing M Lee Alexander Raufi Ilenia Pellicciotta Angela C Hirbe Jaya Pradhan Andrew Chen Raul Rabadan Gary K Schwartz Source Type: research